Deep learning-enabled natural language processing to identify directional pharmacokinetic drug-drug interactions.

Journal: BMC bioinformatics
Published Date: Nov 1, 2023

Abstract

BACKGROUND: During drug development, it is essential to gather information about the change of clinical exposure of a drug (object) due to the pharmacokinetic (PK) drug-drug interactions (DDIs) with another drug (precipitant). While many natural language processing (NLP) methods for DDI have been published, most were designed to evaluate if (and what kind of) DDI relationships exist in the text, without identifying the direction of DDI (object vs. precipitant drug). Here we present a method for the automatic identification of the directionality of a PK DDI from literature or drug labels.

Authors

  • Joel Zirkle
    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.
  • Xiaomei Han
    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.
  • Rebecca Racz
    University of Michigan Medical School, Ann Arbor, MI 48109 USA.
  • Mohammadreza Samieegohar
    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.
  • Anik Chaturbedi
    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.
  • John Mann
    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.
  • Shilpa Chakravartula
    Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, WO Bldg 64 Rm 2078, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.
  • Zhihua Li
    Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.

Keywords

External Resources

Popular Topics
Recent Journals